Last updated: September 4, 2026
Tecovirimat, marketed as TPOXX by SIGA Technologies, is a government-procurement pharmaceutical with limited conventional commercial demand. Its revenue depends primarily on U.S. Strategic National Stockpile purchases, international public-health contracts and episodic mpox demand. SIGA generated approximately $133 million of revenue in 2023, following elevated sales in 2021 and 2022. The core investment case is based on repeat government replenishment, expanded global procurement and potential new indications rather than routine retail prescriptions.
What is the current market position of tecovirimat?
Tecovirimat is an antiviral approved by the U.S. Food and Drug Administration for the treatment of human smallpox caused by variola virus in adults and children. The oral product was approved in 2018, and an intravenous formulation was approved in 2021.[1]
The commercial market is unusual because naturally occurring smallpox has been eradicated. Demand is therefore driven by:
- National biodefense stockpiles
- Government preparedness contracts
- Mpox outbreaks and emergency-access programs
- International public-health procurement
- Potential future approvals for additional orthopoxvirus infections
In the United States, tecovirimat is not broadly sold through retail pharmacies for routine outpatient use. The federal government is the principal customer, with procurement conducted through agencies such as the Biomedical Advanced Research and Development Authority and the Strategic National Stockpile.
What diseases and indications does tecovirimat cover?
| Market or indication |
Regulatory position |
Commercial impact |
| Human smallpox |
FDA-approved |
Primary U.S. label and stockpile use |
| Mpox |
Not generally FDA-approved; available under CDC expanded-access mechanisms |
Demand increased materially during the 2022 outbreak |
| Cowpox and vaccinia complications |
Regulatory coverage varies by jurisdiction |
Secondary opportunity |
| Post-exposure biodefense use |
Government preparedness application |
Supports stockpile procurement |
| Pediatric use |
FDA-approved dosing exists for eligible pediatric patients |
Expands stockpile utility |
The FDA approval was based largely on the Animal Rule because efficacy trials in humans are not feasible for smallpox. Human safety data and animal efficacy studies supported approval.[1]
How has the tecovirimat market developed since 2018?
Tecovirimat sales have followed government purchasing cycles rather than disease prevalence. Stockpile orders create sharp increases in annual revenue, while periods without major deliveries can produce lower sales despite continued strategic importance.
Tecovirimat revenue trajectory
The following figures reflect SIGA Technologies' reported revenue and are rounded where appropriate.
| Fiscal year |
SIGA revenue |
Market driver |
| 2019 |
Approximately $0.1 million |
Limited commercial activity |
| 2020 |
Approximately $32 million |
Early government procurement and contract activity |
| 2021 |
Approximately $125 million |
Strategic stockpile deliveries |
| 2022 |
Approximately $141 million |
U.S. procurement plus mpox-related demand |
| 2023 |
Approximately $133 million |
Continued government orders and international sales |
Sources: SIGA Technologies annual reports and Form 10-K filings.[2-5]
The 2022 mpox outbreak expanded clinical visibility and international demand. The World Health Organization declared the outbreak a public-health emergency of international concern in July 2022, increasing pressure on governments to obtain antivirals, vaccines and diagnostic capacity.[6]
Mpox demand has not converted into a large recurring retail market. Use remains concentrated in patients with severe disease, immunocompromised patients, children, pregnant patients and individuals at elevated risk of complications. That limits prescription volume but supports emergency procurement and preparedness spending.
What drives tecovirimat revenue?
U.S. government stockpile purchases
The U.S. government is the central revenue driver. Stockpile procurement is typically based on:
- Required inventory levels
- Product shelf life
- Replenishment schedules
- National-security assessments
- Available federal appropriations
- Outbreak response planning
This structure gives SIGA a concentrated customer base and creates order volatility. A single large government contract can materially affect annual revenue.
The company has also received contracts connected to BARDA and the U.S. Department of Defense. Government contracts can include delivery milestones, options for additional quantities and multiyear purchasing arrangements.[2-5]
International procurement
International demand expanded after the mpox outbreak. European governments, the United Kingdom, Canada and other countries obtained tecovirimat through direct purchase, public-health channels or emergency-access programs.
European regulatory status is broader than the initial U.S. smallpox label. The European Commission authorized Tecovirimat SIGA for smallpox, monkeypox and cowpox in 2022 under exceptional circumstances.[7]
International sales reduce dependence on the U.S. government but do not create a conventional high-volume commercial market. Most foreign demand remains episodic and tied to public-health preparedness.
Mpox treatment demand
Tecovirimat became the principal antiviral discussed in the U.S. mpox response. The CDC distributed the drug through an expanded-access investigational new drug protocol because the product was not FDA-approved for mpox.[8]
This regulatory pathway supported access but limited standard commercial prescribing. It also means that sustained mpox revenue depends on outbreak severity, federal policy and future clinical or regulatory developments.
What is the financial outlook for SIGA and tecovirimat?
The near-term financial outlook is positive but uneven. Tecovirimat has low manufacturing costs relative to the potential value of a government stockpile contract, and the product has an established regulatory position. Revenue can decline sharply between procurement events.
Financial strengths
SIGA's main financial advantages are:
- A differentiated biodefense product with no broad generic market currently established.
- Government validation through repeated U.S. stockpile purchases.
- High strategic value despite low routine prescription volume.
- A marketed oral product and an approved intravenous formulation.
- Potential demand from multiple national stockpiles.
Financial risks
The principal risks are:
- Revenue concentration in a small number of government customers
- Irregular timing of purchase orders
- Dependence on federal appropriations
- Limited routine commercial demand
- Uncertainty over the duration of mpox-related procurement
- Government pressure on price and contract terms
- Potential future competition from other orthopoxvirus antivirals
- Manufacturing and delivery obligations under public contracts
The stockpile model can produce strong margins during delivery years, but annual revenue should not be extrapolated using conventional prescription-drug growth assumptions. A government order creates a step change in revenue, not necessarily a durable annual run rate.
When does tecovirimat lose regulatory exclusivity?
Tecovirimat's U.S. regulatory exclusivity should be analyzed separately from patent protection.
The oral product received new chemical entity exclusivity, orphan-drug exclusivity and Qualified Infectious Disease Product treatment. The relevant dates depend on the specific dosage form, statutory exclusivity category and FDA listing. The original oral approval occurred in July 2018, while the intravenous product was approved in May 2021.[1]
| Exclusivity category |
General duration |
Relevance to TPOXX |
| New chemical entity |
5 years |
Applies from the original approval |
| Qualified Infectious Disease Product |
Adds 5 years to applicable exclusivity |
Important for anti-infective protection |
| Orphan drug |
7 years for the approved indication |
Applies to the designated indication |
| Pediatric exclusivity |
Adds 6 months if granted after qualifying studies |
Must be confirmed from FDA records |
| IV formulation exclusivity |
Depends on regulatory pathway and listed protections |
Separate analysis from oral capsules |
The QIDP framework can extend market exclusivity for qualifying anti-infective products. For tecovirimat, the practical barrier to near-term generic entry has also depended on regulatory complexity, limited commercial opportunity and the absence of a large retail market.
What patents protect tecovirimat?
Tecovirimat was developed from a small-molecule antiviral patent estate associated with SIGA Technologies. The relevant protection has included composition-of-matter, pharmaceutical-composition and use-related patent families.
The commercial importance of those patents is lower than the strategic value of government purchasing. Even where core patent protection has expired or is approaching expiry, a generic manufacturer would face a limited addressable market, FDA approval requirements and the need to compete for government contracts.
Patent protection versus commercial barriers
| Barrier |
Current commercial importance |
| Core compound patents |
Declining as patents expire |
| Formulation patents |
Relevant to oral and IV products, but narrower than compound claims |
| Method-of-use patents |
Potentially relevant to orthopoxvirus treatment claims |
| Manufacturing know-how |
Material for scale, quality and government qualification |
| Government procurement status |
Highly material |
| Stockpile delivery capability |
Highly material |
| FDA approval for smallpox |
Required for labeled generic substitution |
| Mpox regulatory status |
More complex because U.S. use is generally under expanded access |
The principal market barrier is not a conventional patent thicket. It is the combination of regulatory qualification, government purchasing relationships, manufacturing readiness and uncertain demand.
What is the Orange Book status of TPOXX?
TPOXX is listed in the FDA Orange Book as a prescription drug product. Orange Book analysis must distinguish between:
- Oral capsules
- Intravenous formulation
- Listed patents
- Regulatory exclusivity
- Patent certifications submitted by abbreviated new drug applicants
No major public Paragraph IV litigation involving a generic tecovirimat product had materially disrupted SIGA's market position through the publicly available record reviewed for this analysis. The lack of significant Paragraph IV activity reflects the small commercial market as well as the product's biodefense orientation.
An abbreviated new drug application would still need to address bioequivalence, manufacturing controls, labeling, product quality and any applicable listed patents. For the IV formulation, development and quality requirements may create a higher technical hurdle than for the oral capsule.
Which companies are challenging tecovirimat?
No established generic competitor has materially displaced TPOXX in the U.S. biodefense market. Competitive pressure comes from alternative countermeasures rather than direct generic substitution.
Brincidofovir
Brincidofovir, marketed as Tembexa by Chimerix, was FDA-approved in 2021 for the treatment of human smallpox.[9] It is an alternative smallpox antiviral and may compete for government stockpile funding.
Brincidofovir has a different mechanism, dosing profile and safety considerations. Its presence gives governments an alternative procurement option and reduces dependence on a single antiviral supplier.
Vaccines and immune products
Smallpox vaccines, vaccinia immune globulin and other countermeasures compete for biodefense budgets. These products do not directly substitute for treatment in every patient, but they compete for the same emergency-preparedness funding.
Potential generic manufacturers
A generic entrant could pursue an oral tecovirimat product after applicable regulatory and patent barriers fall. The commercial incentive remains limited because routine retail demand is small and the largest customer is the federal government.
What licensing deals and commercial partnerships affect tecovirimat?
SIGA has relied on government contracts, international commercialization arrangements and distribution relationships rather than a traditional primary-care sales model. The company has also entered agreements supporting access in foreign markets and public-health settings.
The most important commercial relationship is the U.S. government procurement framework. Contract awards, options and amendments determine revenue more directly than physician promotion.
International commercialization arrangements can expand access but may involve lower margins, milestone-based payments or nonexclusive supply obligations. They also increase regulatory and manufacturing complexity across jurisdictions.
What litigation and settlement risks affect TPOXX?
The principal litigation risks are not centered on a major active patent battle. Relevant legal exposure includes:
- Patent challenges by potential generic applicants
- Contract disputes involving government procurement
- Product liability claims
- Pricing or procurement disputes
- Patent ownership and licensing claims
- Regulatory disputes concerning expanded-access use
- Challenges involving international supply arrangements
No widely reported settlement agreement has materially changed the U.S. competitive position of TPOXX through the available public record. The litigation profile is therefore lower than that of blockbuster drugs with large retail markets, although a Paragraph IV filing could change the outlook quickly.
How strong is the tecovirimat patent estate?
The patent estate is commercially adequate but not the principal long-term moat. Core small-molecule protection has aged, and any remaining formulation or method claims are narrower than a new composition-of-matter patent.
The stronger protections are operational:
- Regulatory approval for a biodefense indication
- Government procurement history
- Stockpile qualification
- Manufacturing capacity
- Experience with federal contracting
- Ability to supply oral and IV presentations
- Clinical and regulatory data supporting orthopoxvirus use
This is a government-market franchise rather than a conventional patent-protected branded medicine.
What generic launch scenarios exist for tecovirimat?
Scenario 1: No near-term generic launch
This remains the most commercially plausible scenario when demand is measured against development cost. A generic manufacturer may have little incentive to invest in an FDA filing without a credible government procurement opportunity.
Scenario 2: Oral generic after regulatory exclusivity
An oral generic could enter if a manufacturer establishes bioequivalence and addresses Orange Book patents. The likely initial market would be government tenders rather than retail pharmacy sales.
Scenario 3: Government-led dual sourcing
The U.S. government could encourage additional suppliers to reduce single-source dependence. This would create procurement pressure on SIGA even without widespread retail generic distribution.
Scenario 4: New indication expansion
A formal FDA indication for mpox could increase demand but also invite greater competition. Expanded use would improve the market size while increasing reimbursement, safety and clinical-evidence requirements.
How does tecovirimat compare with competing smallpox antivirals?
| Product |
Company |
FDA smallpox status |
Commercial role |
| TPOXX, tecovirimat |
SIGA Technologies |
Approved, oral and IV |
Leading U.S. stockpile antiviral |
| Tembexa, brincidofovir |
Chimerix |
Approved |
Alternative stockpile antiviral |
| Vaccinia immune globulin |
Various sources |
Countermeasure, not direct antiviral substitute |
Used for selected complications |
| Smallpox vaccines |
U.S. government and manufacturers |
Preventive countermeasure |
Competes for biodefense budgets |
Tecovirimat has the strongest commercial position in the current U.S. government procurement model, but its revenue is more exposed to contract timing. Brincidofovir provides procurement diversification and may limit SIGA's pricing power in future stockpile tenders.
What is the long-term investment outlook for tecovirimat?
Tecovirimat's financial trajectory is best modeled through probability-weighted government contracts rather than market-share forecasts. The product can produce high revenue and cash generation during replenishment cycles, but the baseline between contracts may be substantially lower.
The main upside factors are:
- U.S. stockpile replenishment
- New international purchases
- Persistent mpox transmission or future outbreaks
- Expanded regulatory use
- Additional federal biodefense funding
- Continued preference for dual antivirals in national preparedness programs
The main downside factors are:
- Delayed or reduced government orders
- End of mpox-related emergency demand
- Generic or alternative-antiviral competition
- Federal budget constraints
- Reduced stockpile requirements
- Manufacturing interruptions
Key Takeaways
- Tecovirimat is a government-procurement antiviral, not a conventional retail pharmaceutical.
- SIGA revenue reached approximately $133 million in 2023 after elevated sales in 2021 and 2022.
- The U.S. Strategic National Stockpile remains the principal revenue source.
- Mpox increased international visibility and demand but has not created a large recurring retail market.
- TPOXX has FDA approval for smallpox in oral and IV formulations.
- U.S. mpox access generally relies on CDC expanded-access mechanisms rather than a full FDA treatment indication.
- The patent estate is less important than regulatory qualification, government contracts and supply capability.
- No material generic displacement or major Paragraph IV litigation had been publicly reported through the available record.
- Brincidofovir is the principal direct smallpox-antiviral alternative.
- Future revenue will likely remain volatile because government purchasing cycles determine annual sales.
FAQs
Is tecovirimat a profitable drug for SIGA Technologies?
Yes. Tecovirimat has generated substantial revenue and operating leverage during government delivery years. Profitability remains dependent on contract timing rather than recurring pharmacy prescriptions.
Does the FDA approve tecovirimat for mpox?
No. The FDA approval is for human smallpox. In the United States, tecovirimat has been available for mpox through CDC expanded-access and investigational-use mechanisms.
Can a generic manufacturer sell tecovirimat in the United States?
A generic manufacturer would need FDA approval, satisfy bioequivalence and manufacturing requirements, and address applicable Orange Book patents and exclusivity. No generic product had materially displaced TPOXX in the U.S. market through the reviewed public record.
Is TPOXX included in the Strategic National Stockpile?
Yes. Tecovirimat is a principal antiviral countermeasure held for smallpox preparedness and related orthopoxvirus response needs.
What would most increase the value of SIGA's tecovirimat franchise?
The largest potential drivers are multiyear U.S. stockpile replenishment, expanded international procurement, a formal FDA mpox indication and sustained government preference for multiple antiviral suppliers.
References
- U.S. Food and Drug Administration. (2018). FDA approves the first drug with an indication for treatment of smallpox. https://www.fda.gov
- SIGA Technologies, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- SIGA Technologies, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- SIGA Technologies, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- SIGA Technologies, Inc. (2024). Form 10-K and fourth-quarter financial results for fiscal year 2023.
- World Health Organization. (2022). WHO declares the ongoing monkeypox outbreak a public health emergency of international concern. https://www.who.int
- European Medicines Agency. (2022). Tecovirimat SIGA: EPAR. https://www.ema.europa.eu
- Centers for Disease Control and Prevention. (2022). Expanded access to tecovirimat for mpox. https://www.cdc.gov
- U.S. Food and Drug Administration. (2021). FDA approves drug to treat smallpox. https://www.fda.gov
